(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Land Rover Just Unveiled Its Dakar Rally Defender - 2The most effective method to Really Adjust Hypothesis and Practice in Your Brain science Studies
- 3Civilian toll mounts in Iran as war presses on
- 4\Step by step instructions to Pick the Best Material Organization for Your Home\
- 5Virtual reality opens doors for older people to build closer connections in real life
- Jupiter and the moon take a sunset stroll on March 26. Here's how to see it
- Artemis II crew take new photo of far side of the moon
- Germany to create restitution council to return colonia-era acquired cultural artefacts
- The Most Rousing Ladies Business visionaries of Today
- I decided to become a single mother by choice. I wasn't ready to stop dating.
- Day to day Temporary Positions That Compensate Fairly in the US
- In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros
- How stripping diversity, equity and inclusion from health care may make Americans sicker
- Top 20 Style Brands for Pioneers
